分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

The double inhibition of PDK1 and STAT3-Y705 prevents liver metastasis in colorectal cancer

Qin Wenjuan, Tian Yun, Zhang Jing, Liu Wenjian, Zhou Qiming, Hu Sheng, Yang Fei, Lu Li, Lu Haijie, Cui Shuzhong, Wen Lu, Wei Shaozhong

Journal:Scientific Reports

IF:4.01

DOI:10.1038/s41598-019-49480-8

PMID:

Published:2019-09-10

research field:肿瘤学分子生物学药理学遗传学与基因组学

Abstract

As a key glycolysis enzyme, the significance of pyruvate dehydrogenase kinase 1 (PDK1) in the development of colorectal cancer (CRC) remains unknown. This study revealed that the prognosis of CRC patients with high levels of PDK1 was poor, and PDK1 knockdown significantly reduced liver metastasis of CRC in both nude mice and immune competent BALB/C mice. When combined with cryptotanshinone (CPT), an inhibitor of STAT3-p-Y705, the liver metastasis was further inhibited. PDK1 knockdown obviously increased reactive oxygen species level in anoikis conditions and subsequently resulted in an elevated anoikis, but the combination of PDK1 knockdown and CPT showed a reduced effect on anoikis. Based on this discrepancy, the adherence ability of CRC cells to matrix protein fibronectin was further detected. It showed that PDK1 knockdown significantly decreased the adherence of CRC cells to fibronectin when combined with CPT. These results suggest that inhibition of PDK1 can decrease the surviving CRC cells in blood circulation via up-regulation of anoikis, and inhibition of STAT3-p-Y705 can prevent it to settle down on the liver premetastatic niche, which ultimately reduces liver metastasis.

本文使用的Yeasen产品

购物车
客服
转染试用